John Maraganore is CEO of an increasingly rare breed of firm—the innovative science-based biotech.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Negotiating the RNAi patent thicket
Companies eye slice of age-related macular degeneration market
Silent running: the race to the clinic
Web links
Rights and permissions
About this article
Cite this article
Huggett, B. Profile: John Maraganore. Nat Biotechnol 25, 375–376 (2007). https://doi.org/10.1038/nbt0407-375
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0407-375
This article is cited by
-
The economics of licensing contracts
Bioentrepreneur (2008)